Literature DB >> 26429207

Switching from Intravenous to Subcutaneous Formulation of Abatacept: Different Results in a Series of 21 Patients.

Sara Monti1, Silvia Breda2, Vittorio Grosso2, Monica Todoerti2, Carlomaurizio Montecucco2, Roberto Caporali2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26429207     DOI： 10.3899/jrheum.150230

Source DB:  PubMed          Journal:  J Rheumatol        ISSN： 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  2 in total

Review 1.  Subcutaneous abatacept in rheumatoid arthritis: A real-life experience.

Authors:  Juan Camilo Sarmiento-Monroy; Luisa Parada-Arias; Milena Rodríguez-López; Mónica Rodríguez-Jiménez; Nicolás Molano-González; Adriana Rojas-Villarraga; Rubén Darío Mantilla
Journal:  J Transl Autoimmun       Date:  2019-09-06

2.  Change from subcutaneous to intravenous abatacept and back in patients with rheumatoid arthritis as simulation of a vacation: a prospective phase IV, open-label trial (A-BREAK).

Authors:  Ruediger B Mueller; Michael Gengenbacher; Symi Richter; Jean Dudler; Burkhard Möller; Johannes von Kempis
Journal:  Arthritis Res Ther       Date:  2016-04-14       Impact factor: 5.156
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.